Last reviewed · How we verify
Praga formulation
Praga formulation is a drug that works by targeting the PD-1/PD-L1 pathway to modulate the immune system.
Praga formulation is a drug that works by targeting the PD-1/PD-L1 pathway to modulate the immune system. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | Praga formulation |
|---|---|
| Sponsor | EMS |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1/PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Praga formulation is designed to inhibit the interaction between PD-1 and PD-L1, which can help to restore the body's immune response against cancer cells. This can lead to the reduction of tumor growth and the slowing of disease progression.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |